呋塞米强制利尿与水化对[68Ga]Ga-PSMA-11-PET/CT中晕状伪影及膀胱和肾脏示踪剂聚集强度的影响:前列腺癌患者评估
本研究比较四种准备方案(无准备、仅500 ml氯化钠、500 ml氯化钠+20 mg呋塞米、500 ml氯化钠+40 mg呋塞米)各50例前列腺癌患者[68Ga]Ga-PSMA-11-PET/CT中膀胱和肾脏晕状伪影及示踪剂聚集强度。结果显示20 mg呋塞米联合氯化钠显著减少膀胱晕状伪影数量及膀胱内示踪剂聚集强度,40 mg未进一步改善;肾脏晕状伪影及SUVmean在各组间无显著差异。
要点
- 20 mg呋塞米+500 ml氯化钠显著减少膀胱晕状伪影数量及膀胱SUVmean。
- 40 mg呋塞米未较20 mg进一步减少膀胱晕状伪影或降低膀胱SUVmean。
- 肾脏晕状伪影数量及SUVmean在各组间无统计学显著差异。
核心结论
- 行[68Ga]Ga-PSMA-11-PET/CT时,静脉注射20 mg呋塞米和500 ml氯化钠显著减少膀胱晕状伪影数量并降低膀胱内示踪剂聚集强度。
- 40 mg呋塞米未进一步改善结果。
研究设计与样本
- 研究比较四组各50例接受不同准备方案的前列腺癌患者,行[68Ga]Ga-PSMA-11-PET/CT。
- 组一:无准备;组二:示踪剂注射后立即给予500 ml氯化钠;组三:示踪剂给药后立即给予500 ml氯化钠并注射20 mg呋塞米;组四:示踪剂注射后立即给予500 ml氯化钠并注射40 mg呋塞米。
- 图像视觉判断有无晕状伪影,并用标准化摄取值(SUV)进行半定量测量。
主要发现
- 膀胱晕状伪影:无准备组12例,仅氯化钠组8例,20 mg呋塞米/氯化钠组1例,40 mg呋塞米/氯化钠组2例。
- 膀胱中位SUVmean:无准备组45.8,仅氯化钠组14.4,20 mg呋塞米/氯化钠组4.6,40 mg呋塞米/氯化钠组5.8。
- 无准备组与两个呋塞米/氯化钠组之间差异有统计学意义;20 mg呋塞米组与40 mg呋塞米组之间无显著差异。
- 肾脏晕状伪影:组一15例,组二10例,组三14例,组四14例;对应中位SUVmean分别为33.9、32.0、37.8和30.4,差异无统计学意义。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: to assess the influence of intravenous hydration and forced diuresis with furosemide in two different dosages (20 vs 40 mg) on the intensity of tracer accumulation in the urinary collection system and on the occurrence of halo artefact surrounding the urinary bladder and kidneys in [68Ga]Ga-PSMA-11-PET/CT scans. MATERIALS AND METHODS: Comparison of four groups with 50 patients each, receiving different preparation prior to [68Ga]Ga-PSMA-11-PET/CT. Group one, no preparation. Group two, 500 ml sodium chloride administered immediately after tracer injection. Group three, 500 ml sodium chloride and injection of 20 mg furosemide immediately after tracer administration. Group four, 500 ml sodium chloride and injection of 40 mg furosemide immediately after tracer injection. Images were judged visually whether halo artefact was present; semiquantitative measurements were performed with standardised uptake value (SUV). RESULTS: Halo artefact of the urinary bladder was present in twelve patients without preparation, in eight patients receiving only sodium chloride, in one patient injected with 20 mg furosemide/sodium chloride and in two patients receiving 40 mg furosemide/sodium chloride, showing a median SUVmean in the bladder of 45.8, 14.4, 4.6 and 5.8, respectively. Differences between patient group without preparation and the two groups with furosemide/sodium chloride were statistically significant. Patient groups receiving 20 mg furosemide and 40 mg furosemide did not differ significantly. Renal halo artefacts were observed in 15 patients of group one, in ten patients of group two, in 14 patients of group three and in 14 patients of group four, with corresponding median SUVmean values of 33.9, 32.0, 37.8 and 30.4 (no statistically significant differences). CONCLUSION: Performing [68Ga]Ga-PSMA-11-PET/CT, intravenous injection of 20-mg furosemide and 500-ml sodium chloride significantly reduces the number of bladder halo artefacts and intensity of tracer accumulation in the urinary bladder. A total of 40 mg furosemide does not further improve results.
引用
- Uprimny C, Bayerschmidt S, Kroiss AS, et al. Impact of forced diuresis with furosemide and hydration on the halo artefact and intensity of tracer accumulation in the urinary bladder and kidneys on [68Ga]Ga-PSMA-11-PET/CT in the evaluation of prostate cancer patients. Eur J Nucl Med Mol Imaging. 2020. PMID: 32385647. doi:10.1007/s00259-020-04846-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。